Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial

Add time:08/18/2019    Source:sciencedirect.com

BackgroundCytomegalovirus (CMV) is a leading cause of congenital infection and an important target for vaccine development.

We also recommend Trading Suppliers and Manufacturers of GB 67 (cas 116784-70-4). Pls Click Website Link as below: cas 116784-70-4 suppliers

Prev:Original Research ReportKi-67 labeling index in glioblastoma; does it really matter?
Next:Research paperExploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors)